Company NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.12 ^USD	+2.30%		-25.36%	-32.17%

Apr. 18	NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq	MT
Apr. 18	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches	MT

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

Managers	Title	Age	Since
Stephen Willard CEO	Chief Executive Officer	63	22-07-11
Jonathan Javitt FOU	Founder	67	17-09-17
Richard Narido DFI	Director of Finance/CFO	46	23-09-12
Carrie M. Carretta CTO	Chief Tech/Sci/R&D Officer	-	22-12-04
Rick Panicucci CTO	Chief Tech/Sci/R&D Officer	63	-
Dennis K. McBride PRN	Corporate Officer/Principal	-	15-09-30

Members of the board	Title	Age	Since
Jonathan Javitt FOU	Founder	67	17-09-17
Stephen Willard CEO	Chief Executive Officer	63	22-07-11
Janet Rehnquist BRD	Director/Board Member	-	Dec. 26
Patrick J. Flynn BRD	Director/Board Member	75	21-05-23
Chaim Hurvitz BRD	Director/Board Member	63	21-05-23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,488,067	7,612,875 ( 72.59 %)	0	72.59 %
Stock B	0	3,000,000	0	0

Name	Equities	%	Valuation
Jonathan Javitt 15.98 %	14,768,329	15.98 %	7 M $
Chaim Hurvitz 2.396 %	2,214,793	2.396 %	1 M $
Vanguard Group, Inc. (Subfiler) 1.564 %	1,445,177	1.564 %	682 124 $
Stephen Willard 1.136 %	1,050,000	1.136 %	495 600 $
AdvisorShares Investments LLC 0.6953 %	642,632	0.6953 %	303 322 $
Patrick Flynn 0.6387 %	590,336	0.6387 %	278 639 $
Geode Capital Management LLC 0.4457 %	411,922	0.4457 %	194 427 $
BlackRock Institutional Trust Co. NA 0.3145 %	290,714	0.3145 %	137 217 $
Renaissance Technologies LLC 0.2169 %	200,480	0.2169 %	94 627 $
RBC CMA LLC 0.1625 %	150,209	0.1625 %	70 899 $

Name	Equities	%	Valuation
Yakira Capital Management, Inc. -	15,409	-	2 897 $
Wolverine Asset Management LLC -	7,657	-	1 440 $
Tower Research Capital LLC -	15	-	3 $

NRX Pharmaceuticals, Inc.

1201 Orange Street Suite 600

19801, Wilmington

http://www.nrxpharma.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.12 USD

Average target price

37.5 USD

Spread / Average Target

+1,101.92%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NRX PHARMACEUTICALS, INC.	-32.17%	32.51M
IQVIA HOLDINGS INC.	+4.09%	43.84B
MODERNA, INC.	+9.45%	41.68B
LONZA GROUP AG	+46.28%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research